Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The operating income for Intensity Therapeutics, Inc. as of June 30, 2025 is -12.87 MM.
- The net income for Intensity Therapeutics, Inc. as of June 30, 2025 is -12.58 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | -12.87 | -12.58 | |
2025-03-31 | -15.24 | -15.01 | |
2024-12-31 | -16.59 | -16.27 | |
2024-09-30 | -16.73 | -16.26 | |
2024-06-30 | -15.65 | -15.07 | |
2024-03-31 | -11.81 | -13.80 | |
2023-12-31 | -8.32 | -10.54 | |
2023-09-30 | -6.44 | -8.88 | |
2023-06-30 | -5.72 | -8.32 | |
2023-03-31 | -6.43 | -6.55 | |
2022-12-31 | -7.55 | -7.58 | |
2022-09-30 | -8.49 | -8.47 | |
2022-06-30 | -8.86 | -8.82 | |
2022-03-31 | -8.89 | -8.79 | |
2021-12-31 | -8.01 | -7.90 | |
2021-09-30 | -7.26 | -7.13 | |
2021-06-30 | -6.77 | -6.56 | |
2021-03-31 | -6.26 | -6.09 | |
2020-12-31 | -6.22 | -6.03 |
Income Statement: EPS
- The earnings per share basic for Intensity Therapeutics, Inc. as of June 30, 2025 is -0.81.
- The earnings per share diluted for Intensity Therapeutics, Inc. as of June 30, 2025 is -0.81.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -0.81 | -0.81 |
2025-03-31 | -1.05 | -1.05 |
2024-12-31 | -1.17 | |
2024-09-30 | -1.18 | -1.18 |
2024-06-30 | -1.10 | -1.10 |
2024-03-31 | -1.35 | -1.35 |
2023-12-31 | -1.38 | |
2023-09-30 | -1.69 | -1.69 |
2023-06-30 | -2.81 | -2.81 |
2023-03-31 | -1.92 | -1.92 |
2022-12-31 | -2.22 | |
2022-09-30 | -2.48 | -2.48 |
2022-06-30 | -2.59 | -2.59 |
2022-03-31 | -2.58 | -2.58 |
2021-12-31 | -2.32 | |
2021-09-30 | -2.09 | -2.09 |
2021-06-30 | -1.92 | -1.92 |
2021-03-31 | -1.79 | -1.79 |
2020-12-31 | -1.77 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Intensity Therapeutics, Inc. as of June 30, 2025 is -11.09 MM.
- The cash from investing activities for Intensity Therapeutics, Inc. as of June 30, 2025 is 3.10 MM.
- The cash from financing activities for Intensity Therapeutics, Inc. as of June 30, 2025 is 6.96 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -11.09 | 3.10 | 6.96 |
2025-03-31 | -12.84 | 3.09 | 3.22 |
2024-12-31 | -15.22 | 6.35 | 2.90 |
2024-09-30 | -13.50 | 9.18 | 0.41 |
2024-06-30 | -14.64 | -2.77 | 20.52 |
2024-03-31 | -10.67 | -2.76 | 20.27 |
2023-12-31 | -7.21 | -6.02 | 20.47 |
2023-09-30 | -7.89 | -8.84 | 22.73 |
2023-06-30 | -3.80 | 2.21 | |
2023-03-31 | -4.89 | 2.47 | |
2022-12-31 | -5.48 | 2.25 | |
2022-09-30 | -6.71 | 0.00 | |
2022-06-30 | -7.18 | 2.05 | |
2022-03-31 | -7.11 | 2.04 | |
2021-12-31 | -6.83 | 2.05 | |
2021-09-30 | -5.68 | 7.90 | 2.05 |
2021-06-30 | -5.30 | 4.90 | 2.60 |
2021-03-31 | -5.31 | 4.73 | 4.45 |
2020-12-31 | -5.37 | 4.56 | 6.29 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/e for Intensity Therapeutics, Inc. as of June 30, 2025 is -0.31.
- The p/book for Intensity Therapeutics, Inc. as of June 30, 2025 is 13.94.
- The p/tbv for Intensity Therapeutics, Inc. as of June 30, 2025 is 13.94.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -0.31 | 13.94 | 13.94 |
2025-03-31 | 10.14 | 10.14 | |
2024-12-31 | 9.89 | 9.89 | |
2024-09-30 | -3.50 | 9.87 | 9.87 |
2024-06-30 | -4.97 | 7.05 | 7.05 |
2024-03-31 | -6.57 | 5.26 | 5.26 |
2023-12-31 | -13.22 | 7.38 | 7.38 |
2023-09-30 | -6.53 | 3.59 | 3.59 |
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for Intensity Therapeutics, Inc. as of June 30, 2025 is -4.03.
- The ebit (3y)/ev for Intensity Therapeutics, Inc. as of June 30, 2025 is -3.44.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -4.03 | -3.44 |
2025-03-31 | -0.60 | -0.45 |
2024-12-31 | -0.66 | -0.46 |
2024-09-30 | -0.30 | -0.22 |
2024-06-30 | -0.23 | -0.11 |
2024-03-31 | -0.17 | -0.10 |
2023-12-31 | -0.08 | -0.03 |
2023-09-30 | -0.15 | -0.09 |
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 |
Management Effectiveness
- The roa for Intensity Therapeutics, Inc. as of June 30, 2025 is -1.73.
- The roe for Intensity Therapeutics, Inc. as of June 30, 2025 is -2.81.
- The roic for Intensity Therapeutics, Inc. as of June 30, 2025 is -32.28.
- The croic for Intensity Therapeutics, Inc. as of June 30, 2025 is -14.04.
- The ocroic for Intensity Therapeutics, Inc. as of June 30, 2025 is -27.62.
Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
2025-06-30 | -1.73 | -2.81 | -32.28 | -14.04 | -27.62 |
2025-03-31 | -1.31 | -1.67 | -5.32 | -1.95 | -4.98 |
2024-12-31 | -0.94 | -1.24 | -5.56 | -1.34 | -4.62 |
2024-09-30 | -0.90 | -0.95 | -2.74 | 0.56 | -2.66 |
2024-06-30 | -14.51 | -1.40 | 0.69 | -1.08 | |
2024-03-31 | -6.00 | -0.79 | 0.54 | -0.54 | |
2023-12-31 | -0.55 | 0.37 | -0.49 | ||
2023-09-30 | -0.55 | -0.10 | -0.25 | ||
2023-06-30 | 0.00 | -0.55 | -0.10 | ||
2023-03-31 | |||||
2022-12-31 | |||||
2022-09-30 | -2.45 | ||||
2022-06-30 | -1.67 | ||||
2022-03-31 | 0.00 | ||||
2021-12-31 | 0.00 | 0.00 | |||
2021-09-30 | -1.22 | 0.73 | -0.97 | ||
2021-06-30 | -0.73 | -1.15 | 0.39 | -12.84 | |
2021-03-31 | -0.68 | -12.24 | 7.77 | -10.68 | |
2020-12-31 | -0.68 | -0.79 | -0.67 | 0.61 | -0.60 |
Gross Margins
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 |
Identifiers and Descriptors
Central Index Key (CIK) | 1567264 |